Breaking News Instant updates and real-time market news.

2022-04-20 08:30:03 DTC Solo Brands $6.35 / +0.12 (+1.93%) , WTRE Watford Holdings $22.81 / -0.11 (-0.48%) … 08:30 04/20/22 04/20 08:30 04/20/22 08:30	Five new option listings and one option delisting on April 20th New option listings for April 20th include Solo Brands Inc (DTC), WTRE ETF (WTRE), Ferguson Plc (FERG), INDUS Realty Trust Inc (INDT), and Sight Sciences Inc (SGHT). Option delistings effective April 20th include WisdomTree Global ex US Real Estate Fund (DRW). DTC Solo Brands $6.35 / +0.12 (+1.93%) WTRE Watford Holdings $22.81 / -0.11 (-0.48%) FERG Ferguson $135.58 / +3.63 (+2.75%) INDT Indus Realty Trust $74.28 / +0.62 (+0.84%) SGHT Sight Sciences $9.21 / +0.475 (+5.44%)	22 Apr 22 Apr 10 May 10 May 26 May 15 Jul 06 Oct 28 Oct

2022-04-20 08:30:03

DTC

Solo Brands

$6.35 / +0.12 (+1.93%)

, WTRE

Watford Holdings

$22.81 / -0.11 (-0.48%)

… 08:30

04/20/22

04/20

08:30

04/20/22

08:30

Five new option listings and one option delisting on April 20th

New option listings for April 20th include Solo Brands Inc (DTC), WTRE ETF (WTRE), Ferguson Plc (FERG), INDUS Realty Trust Inc (INDT), and Sight Sciences Inc (SGHT). Option delistings effective April 20th include WisdomTree Global ex US Real Estate Fund (DRW).

DTC

Solo Brands

$6.35 / +0.12 (+1.93%)

WTRE

Watford Holdings

$22.81 / -0.11 (-0.48%)

FERG

Ferguson

$135.58 / +3.63 (+2.75%)

INDT

Indus Realty Trust

$74.28 / +0.62 (+0.84%)

SGHT

Sight Sciences

$9.21 / +0.475 (+5.44%)

22
Apr
22
Apr
10
May
10
May
26
May

15
Jul
06
Oct
28
Oct

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks	Enthusiast Gaming updates senior management team, names John Albright chairman » 17:51 08/08/22 08/08 17:51 08/08/22 17:51 EGLX Enthusiast Gaming $1.94 / +0.05 (+2.65%) Enthusiast Gaming… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research EGLX Enthusiast Gaming $1.94 / +0.05 (+2.65%) 07/07/22 Enthusiast Gaming to initiate search for new CEO following role switch 07/07/22 Enthusiast Gaming announces two nominees from Greywood Investments to join board 06/30/22 Enthusiast Gaming issued letter to shareholders 06/27/22 Greywood Investments issues letter to Enthusiast Gaming shareholders EGLX Enthusiast Gaming $1.94 / +0.05 (+2.65%) 07/19/22 B. Riley Enthusiast Gaming price target lowered to C$7.25 from C$11.50 at B. Riley 05/17/22 RBC Capital Enthusiast Gaming price target raised to C$8 from C$7 at RBC Capital 03/29/22 Scotiabank Enthusiast Gaming price target lowered to C$8 from C$8.25 at Scotiabank 03/24/22 Scotiabank Enthusiast Gaming price target lowered to C$8.25 from C$9.75 at Scotiabank
Periodicals	U.S. judge skeptical of Ben & Jerry's claims against Unilever, Reuters says » 17:49 08/08/22 08/08 17:49 08/08/22 17:49 UL Unilever $48.41 / +0.34 (+0.71%) , UN Use symbol UL $60.50 / + (+0.00%) U.S. District Judge… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events UL UN UL Unilever $48.41 / +0.34 (+0.71%) 07/20/22 Unilever Food Solutions U.S. recalls Knorr Professional Soup du Jour soup mix 06/29/22 Unilever sells Ben & Jerry's business interests in Israel to current licensee 06/29/22 Unilever expands partnership with Numerator 06/16/22 Unilever, Genomatica launch $120M JV for alternative to palm oil ingredients UN Use symbol UL $60.50 / + (+0.00%) 07/20/22 Unilever Food Solutions U.S. recalls Knorr Professional Soup du Jour soup mix 05/11/22 AXA, Unilever, Tikehau Capital sign MOU to create impact fund UL UN UL Unilever $48.41 / +0.34 (+0.71%) 07/27/22 DZ Bank Unilever downgraded to Hold from Buy at DZ Bank 07/26/22 Deutsche Bank Unilever upgraded at Deutsche Bank as commodity headwinds flip to tailwinds 07/26/22 Deutsche Bank Unilever upgraded to Buy from Hold at Deutsche Bank 07/22/22 Bernstein Unilever upgraded to Outperform from Market Perform at Bernstein UN Use symbol UL $60.50 / + (+0.00%) 01/17/22 Bernstein Unilever downgraded to Underperform from Market Perform at Bernstein 01/17/22 Barclays Unilever downgraded to Equal Weight from Overweight at Barclays 01/10/22 Citi Unilever resumed with a Buy at Citi 11/01/21 Bernstein Unilever upgraded to Market Perform from Underperform at Bernstein UL UL Unilever $48.41 / +0.34 (+0.71%) 07/26/22 Unilever raises 2022 sales growth view 07/26/22 Unilever reports Q1 EPS EUR1.34, up 1% y/y UL UN UL Unilever $48.41 / +0.34 (+0.71%) 08/03/22 Unilever ceases paying Ben & Jerry's independent board members, FT reports 08/01/22 Ben & Jerry's talks with Unilever over Israel unit sale break down, Reuters says 07/26/22 Unilever raised prices 11% in Q2, FT reports 07/05/22 Ben & Jerry's sues Unilever to block Israeli business sale, Reuters reports UN Use symbol UL $60.50 / + (+0.00%) 08/01/22 Ben & Jerry's talks with Unilever over Israel unit sale break down, Reuters says UL UL Unilever $48.41 / +0.34 (+0.71%) 07/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/31/22 What You Missed On Wall Street On Tuesday 05/31/22 What You Missed On Wall Street This Morning 05/31/22 Fly Intel: Pre-market Movers 09/19/22 Groceryshop
Hot Stocks	Clover Health CEO Vivek Garipalli to switch roles, Andrew Toy to succeed » 17:47 08/08/22 08/08 17:47 08/08/22 17:47 CLOV Clover Health $3.40 / +0.14 (+4.30%) , GOOG Alphabet $118.17 / -0.11 (-0.09%) , GOOGL Alphabet $117.32 / -0.17 (-0.14%) Clover Health (CLOV)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options CLOV GOOG GOOGL CLOV Clover Health $3.40 / +0.14 (+4.30%) 07/14/22 Clover Health announces planned medicare edvantage expansion for 2023 06/24/22 Clover Health is set to join the Russell 3000 Index 05/25/22 Clover Health appoints Scott Leffler as CFO 03/14/22 Clover Health appoints Joseph Martin as general counsel GOOG Alphabet $118.17 / -0.11 (-0.09%) 08/02/22 Mandiant to not provide guidance due to pending transaction with Google 08/02/22 Thryv and Google team to streamline communication for small businesses 07/31/22 Fly Intel: Top five weekend stock stories 07/29/22 Google says Stadia game streaming service not shutting down GOOGL Alphabet $117.32 / -0.17 (-0.14%) 08/02/22 Mandiant to not provide guidance due to pending transaction with Google 07/31/22 Fly Intel: Top five weekend stock stories 07/29/22 Google says Stadia game streaming service not shutting down 07/28/22 Google updates Play Store policies around intrusive advertisements CLOV GOOG GOOGL CLOV Clover Health $3.40 / +0.14 (+4.30%) 02/24/22 Canaccord Clover Health price target raised to $7 from $6 at Canaccord 02/17/22 Citi Citi opens 'negative catalyst watches' in health care services 02/02/22 Cowen Clover Health upgraded to Market Perform from Underperform at Cowen 01/19/22 SVB Leerink Clover Health initiated with a Market Perform at SVB Leerink GOOG Alphabet $118.17 / -0.11 (-0.09%) 08/03/22 Tigress Financial Alphabet price target raised to $186 from $183 at Tigress Financial 07/27/22 Truist Chrome cookie phase-out delay positive for Criteo, says Truist 07/27/22 KeyBanc Google's cookie phase-out delay not surprising, says KeyBanc 07/27/22 RBC Capital Google cookie phase-out delay adds another year of uncertainty, says RBC Capital GOOGL Alphabet $117.32 / -0.17 (-0.14%) 08/03/22 Tigress Financial Alphabet price target raised to $186 from $183 at Tigress Financial 07/27/22 Truist Chrome cookie phase-out delay positive for Criteo, says Truist 07/27/22 KeyBanc Google's cookie phase-out delay not surprising, says KeyBanc 07/27/22 RBC Capital Google cookie phase-out delay adds another year of uncertainty, says RBC Capital CLOV GOOG GOOGL CLOV Clover Health $3.40 / +0.14 (+4.30%) 17:16 Today Clover Health reports Q2 revenue $846.7M, consensus $814.62M 05/09/22 Clover Health reaffirms FY22 revenue view $3.0B-$3.4B, consensus $3.24B 05/09/22 Clover Health reports Q1 revenue $874.4M, consensus $787.41M 02/23/22 Clover Health sees FY22 revenue $3.0B-$3.4B, consensus $2.62B GOOG Alphabet $118.17 / -0.11 (-0.09%) 07/26/22 Alphabet reports Q2 EPS $1.21, consensus $1.30 07/26/22 Notable companies reporting after market close 04/26/22 Alphabet reports Q1 EPS $24.62, consensus $25.96 04/26/22 Notable companies reporting after market close GOOGL Alphabet $117.32 / -0.17 (-0.14%) 07/26/22 Alphabet reports Q2 EPS $1.21, consensus $1.30 07/26/22 Notable companies reporting after market close 04/26/22 Alphabet reports Q1 EPS $24.62, consensus $25.96 04/26/22 Notable companies reporting after market close 18 Nov GOOG GOOGL GOOG Alphabet $118.17 / -0.11 (-0.09%) 08:16 Today Google files two more patent lawsuits against Sonos, Bloomberg Law reports 08/04/22 EU antitrust enforcers to investigate Google Play Store rules, Politico reports 08/02/22 Rumble allowed to proceed with antitrust suit against Google, Verge reports 08/01/22 Amazon hires senior congressional aide to fight antitrust bill, Bloomberg says GOOGL Alphabet $117.32 / -0.17 (-0.14%) 08:16 Today Google files two more patent lawsuits against Sonos, Bloomberg Law reports 08/04/22 EU antitrust enforcers to investigate Google Play Store rules, Politico reports 08/02/22 Rumble allowed to proceed with antitrust suit against Google, Verge reports 08/01/22 Amazon hires senior congressional aide to fight antitrust bill, Bloomberg says CLOV GOOG GOOGL CLOV Clover Health $3.40 / +0.14 (+4.30%) 05/10/22 Fly Intel: Pre-market Movers 05/09/22 Fly Intel: After-Hours Movers 02/24/22 What You Missed On Wall Street On Thursday 02/24/22 What You Missed On Wall Street This Morning GOOG Alphabet $118.17 / -0.11 (-0.09%) 16:46 Today What You Missed On Wall Street On Monday 12:12 Today What You Missed On Wall Street This Morning 08/04/22 What You Missed On Wall Street This Morning 08/03/22 #SocialStocks: Five-day trial between Twitter and Elon Musk set for October 17 GOOGL Alphabet $117.32 / -0.17 (-0.14%) 16:46 Today What You Missed On Wall Street On Monday 12:12 Today What You Missed On Wall Street This Morning 08/04/22 What You Missed On Wall Street This Morning 08/03/22 #SocialStocks: Five-day trial between Twitter and Elon Musk set for October 17 17:00 Today Clover Health - CLOV CLOV GOOG GOOGL CLOV Clover Health $3.40 / +0.14 (+4.30%) 13:34 Today Clover Health options imply 12.4% move in share price post-earnings 07/18/22 Unusually active option classes on open July 18th 06/27/22 Unusually active option classes on open June 27th 06/21/22 Unusually active option classes on open June 21st GOOG Alphabet $118.17 / -0.11 (-0.09%) 07/26/22 Alphabet options imply 6.1% move in share price post-earnings 07/25/22 Unusually active option classes on open July 25th 07/25/22 Alphabet put buyer realizes 47% same-day gains 07/22/22 Unusually active option classes on open July 22nd GOOGL Alphabet $117.32 / -0.17 (-0.14%) 07/27/22 Notable open interest changes for July 27th 07/26/22 Alphabet Class A options imply 6.1% move in share price post-earnings 07/25/22 Unusually active option classes on open July 25th 07/22/22 Unusually active option classes on open July 22nd
Hot Stocks	Horizon Global announces review of strategic alternatives » 17:46 08/08/22 08/08 17:46 08/08/22 17:46 HZN Horizon Global $1.38 / +0.035 (+2.60%) Horizon Global announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Events HZN Horizon Global $1.38 / +0.035 (+2.60%) 07/29/22 Horizon Global addresses NYSE continued listing standards 06/29/22 Horizon Global appoints Jian James Zhou as CFO 06/08/22 Horizon Global and Continental settle patent dispute 02/14/22 Horizon Global rises 10.6% 08/09/22 Horizon Global - HZN
Earnings	Cara Therapeutics reports Q2 EPS (8c), consensus (25c) » 17:43 08/08/22 08/08 17:43 08/08/22 17:43 CARA Cara Therapeutics $11.50 / +0.215 (+1.91%) Reports Q2 revenue $23M,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events CARA Cara Therapeutics $11.50 / +0.215 (+1.91%) 06/30/22 Cara Therapeutics announces results from Phase 2 trial of difelikefalin 06/06/22 Amarin CFO Michael Kalb resigns, Tom Reilly to succeed 06/03/22 Cara Therapeutics CFO Thomas Reilly resigns, Richard Makara named interim CFO 04/28/22 Vifor Fresenius, Cara announces European Commission authorization for Kapruvia CARA Cara Therapeutics $11.50 / +0.215 (+1.91%) 05/10/22 H.C. Wainwright H.C. Wainwright sees 'major valuation disconnect' at Cara Therapeutics 03/14/22 Canaccord Cara Therapeutics price target lowered to $29 from $33 at Canaccord 03/08/22 JPMorgan Cara Therapeutics upgraded to Overweight from Neutral at JPMorgan 11/01/21 Canaccord Cara Therapeutics assumed with a Buy at Canaccord CARA Cara Therapeutics $11.50 / +0.215 (+1.91%) 05/09/22 Cara Therapeutics reports Q1 EPS (52c), consensus (54c) 03/01/22 Cara Therapeutics reports Q4 EPS (63c), consensus (52c) 00:00 Today 42nd Annual Global I Growth Conference 16:30 Today Cara Therapeutics - CARA
Earnings	Chimerix reports Q2 EPS (27c), consensus (24c) » 17:36 08/08/22 08/08 17:36 08/08/22 17:36 CMRX Chimerix $2.36 / -0.325 (-12.13%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events CMRX Chimerix $2.36 / -0.325 (-12.13%) 07:22 Today Chimerix appoints Jordan as VP, Regulatory Affairs 08/04/22 Siga, Chimerix rallyafter WaPo report of monkeypox emergency declaration 06/24/22 Chimerix announces $25.3M TEMBEXA procurement agreement 06/23/22 Chimerix announces $9.3M TEMBEXA procurement agreement CMRX Chimerix $2.36 / -0.325 (-12.13%) 05/20/22 Benchmark Benchmark says Emergent, Siga, Chimerix strength attributable to monkeypox scare 05/16/22 H.C. Wainwright Chimerix price target lowered to $11 from $24 at H.C. Wainwright 12/22/21 H.C. Wainwright Chimerix price target raised to $24 from $21 at H.C. Wainwright 11/22/21 H.C. Wainwright Chimerix price target raised to $21 from $19 at H.C. Wainwright CMRX Chimerix $2.36 / -0.325 (-12.13%) 05/16/22 Chimerix reports Q1 EPS (28c), consensus (33c) 03/01/22 Chimerix reports Q4 EPS (45c), consensus (17c) 15 Sep CMRX Chimerix $2.36 / -0.325 (-12.13%) 08/04/22 Biden to declare monkeypox public health emergency, Washington Post says 07/25/22 WHO declares monkeypox outbreak global health emergency, CNBC reports CMRX Chimerix $2.36 / -0.325 (-12.13%) 08/04/22 What You Missed On Wall Street On Thursday 07/25/22 These vaccine makers are jumping after monkeypox declared global emergency 05/27/22 As Monkeypox cases rise, so do shares of Siga 05/16/22 What You Missed On Wall Street On Monday 08/09/22 Wedbush PacGrow Healthcare Virtual Conference 16:30 Today Chimerix - CMRX
Hot Stocks	Ur-Energy signs agreement with U.S. nuclear utility » 17:35 08/08/22 08/08 17:35 08/08/22 17:35 URG Ur-Energy $1.18 / -0.01 (-0.84%) Ur-Energy announce that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research Periodicals URG Ur-Energy $1.18 / -0.01 (-0.84%) 11/02/21 Alliance Global Partners Ur-Energy price target raised to $2.50 from $2.20 at Alliance Global Partners URG Ur-Energy $1.18 / -0.01 (-0.84%) 04/18/22 Energy Department set to announce $6B nuclear plant lifeline, Bloomberg says
Earnings	Mesa Air reports Q3 EPS (28c), consensus (22c) » 17:34 08/08/22 08/08 17:34 08/08/22 17:34 MESA Mesa Air $2.66 / +0.135 (+5.35%) Reports Q3 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events MESA Mesa Air $2.66 / +0.135 (+5.35%) 06/08/22 Mesa Air announces enhanced United Aviate partnership 04/22/22 Mesa Air appoints Amy Krallman as VP, human resources 03/01/22 Mesa Air appoints Christian Daoud as VP, maintenance and technical operations MESA Mesa Air $2.66 / +0.135 (+5.35%) 05/11/22 Deutsche Bank Mesa Air price target lowered to $3 from $5.50 at Deutsche Bank 02/04/22 Raymond James Mesa Air downgraded to Market Perform from Outperform at Raymond James 02/04/22 Raymond James Mesa Air downgraded to Market Perform from Outperform at Raymond James 01/07/22 BofA Mesa Air downgraded to Neutral from Buy at BofA MESA Mesa Air $2.66 / +0.135 (+5.35%) 05/09/22 Mesa Air reports Q2 EPS ( 29c), consensus (31c) 02/09/22 Mesa Air reports Q EPS (26c), consensus (12c) 16:30 Today Mesa Air - MESA
Hot Stocks	National Healthcare announces $25M stock repurchase authorization » 17:31 08/08/22 08/08 17:31 08/08/22 17:31 NHC National Healthcare $69.31 / +1.14 (+1.67%) National HealthCare… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Earnings NHC National Healthcare $69.31 / +1.14 (+1.67%) 05/05/22 National Healthcare raises quarterly dividend by 3.6% to 57c per share NHC National Healthcare $69.31 / +1.14 (+1.67%) 02/18/22 National Healthcare reports Q4 adjusted EPS $1.02 vs. 90c last year
Hot Stocks	CorMedix receives CRL from FDA saying that DefenCath NDA cannot be approved » 17:31 08/08/22 08/08 17:31 08/08/22 17:31 CRMD CorMedix $7.50 / +0.39 (+5.49%) CorMedix announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Earnings On The Fly Events CRMD CorMedix $7.50 / +0.39 (+5.49%) 05/12/22 CorMedix believes it has sufficient resources to fund through 1H of 2023 05/12/22 CorMedix announces leadership updates, operational changes 04/07/22 CorMedix announces SAB to support commercialization, pipeline development 03/28/22 CorMedix announces FDA acceptance of resubmission of NDA for DefenCath CRMD CorMedix $7.50 / +0.39 (+5.49%) 05/12/22 CorMedix reports Q1 EPS (18c), consensus (22c) 03/29/22 CorMedix reports Q4 EPS (20c), consensus (23c) CRMD CorMedix $7.50 / +0.39 (+5.49%) 03/29/22 Fly Intel: After-Hours Movers 08/11/22 CorMedix - CRMD

Syndicate	Cyteir Therapeutics files $300M mixed securities shelf 17:30 08/08/22 08/08 17:30 08/08/22 17:30 CYT Cyteir Therapeutics $2.58 / +0.09 (+3.61%) ShowHide Related Items >><< Company News Street Research Earnings Events CYT Cyteir Therapeutics $2.58 / +0.09 (+3.61%) 16:08 Today Cyteir Therapeutics expects cash to fund operations into second half of 2024 06/05/22 Cyteir Therapeutics presents CYT-0851 Phase 1 dose escalation results 04/25/22 Cyteir Therapeutics appoints Adam Veness as general counsel CYT Cyteir Therapeutics $2.58 / +0.09 (+3.61%) 03/17/22 Wedbush Cyteir Therapeutics price target lowered to $30 from $40 at Wedbush 02/07/22 Northland Cyteir Therapeutics initiated with an Outperform at Northland CYT Cyteir Therapeutics $2.58 / +0.09 (+3.61%) 16:08 Today Cyteir Therapeutics reports Q2 EPS (34c), consensus (44c) 05/05/22 Cyteir Therapeutics reports Q1 EPS (40c), consensus (39c) 03/16/22 Cyteir Therapeutics reports Q4 EPS (34c), consensus (39c) 00:00 Today Biotechnology Conference 08/09/22 Wedbush PacGrow Healthcare Virtual Conference
Syndicate	Biolase files to sell 1.41M shares of common stock for holders 17:30 08/08/22 08/08 17:30 08/08/22 17:30 BIOL Biolase $5.40 / +0.12 (+2.27%) ShowHide Related Items >><< Company News Street Research Earnings Events BIOL Biolase $5.40 / +0.12 (+2.27%) 07/25/22 Biolase receives five new United States patents, seven new foreign patents 07/13/22 Biolase announces pilot program with Einstein Healthcare Network's residency 07/07/22 Biolase promotes Jennifer Bright to CFO, Steven Sandor to COO 07/05/22 Biolase announces partnership with TeamSmile BIOL Biolase $5.40 / +0.12 (+2.27%) 05/20/22 Lake Street Biolase initiated with a Buy at Lake Street 08/19/21 Ascendiant Biolase price target raised to $3 from $2 at Ascendiant BIOL Biolase $5.40 / +0.12 (+2.27%) 05/12/22 Biolase sees Q2 revenue above $10.5M, consensus $10.2M 05/12/22 Biolase reports Q1 EPS (77c), consensus (68c) 08/11/22 Biolase - BIOL
Syndicate	CinCor Pharma files to sell 6M shares of common stock, pre-funded warrants » 17:29 08/08/22 08/08 17:29 08/08/22 17:29 CINC CinCor Pharma $34.96 / +11.46 (+48.77%) Goldman Sachs & Co.,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options CINC CinCor Pharma $34.96 / +11.46 (+48.77%) 07:24 Today CinCor Pharma announces data for Phase 2 BrigHtn trial evaluating baxdrostat 07:21 Today CinCor Pharma announces upcoming milestones 07/26/22 CinCor Pharma announces last patient randomized in Phase 2 HALO trial 06/01/22 CinCor Pharma doses first patient in Phase 2 figHTN-CKD trial CINC CinCor Pharma $34.96 / +11.46 (+48.77%) 14:35 Today Oppenheimer CinCor Pharma price target raised to $60 from $35 at Oppenheimer 07/21/22 Oppenheimer CinCor Pharma price target raised to $35 from $30 at Oppenheimer 02/01/22 Oppenheimer CinCor Pharma initiated with an Outperform at Oppenheimer 02/01/22 Evercore ISI CinCor Pharma initiated with an Outperform at Evercore ISI CINC CinCor Pharma $34.96 / +11.46 (+48.77%) 07:20 Today CinCor Pharma reports Q2 EPS (56c), consensus (50c) 05/10/22 CinCor Pharma reports Q1 EPS (50c), consensus (50c) 03/22/22 CinCor Pharma reports Q4 EPS ($15.71) vs. ($4.65) last year 07 Jan CINC CinCor Pharma $34.96 / +11.46 (+48.77%) 16:46 Today What You Missed On Wall Street On Monday 12:12 Today What You Missed On Wall Street This Morning 03/26/22 Opening Day: AN2 Therapeutics rises in public debut after upsized IPO 08:30 Today CinCor Pharma - CINC CINC CinCor Pharma $34.96 / +11.46 (+48.77%) 07/13/22 Two new option listings on July 13th
Earnings	Primoris reports Q2 adjusted EPS 48c, two estimates 59c » 17:29 08/08/22 08/08 17:29 08/08/22 17:29 PRIM Primoris $22.52 / +0.095 (+0.42%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events PRIM Primoris $22.52 / +0.095 (+0.42%) 07/05/22 Primoris awarded contract at over $170M 06/27/22 Primoris enter agreement to acquire PLH in all-cash transaction valued at $470M 06/23/22 Primoris awarded $260M solar project 05/06/22 Primoris awarded $130M solar project PRIM Primoris $22.52 / +0.095 (+0.42%) 11/10/21 Goldman Sachs Goldman downgrades Primoris to Sell on 'bottom quintile' growth 11/10/21 Goldman Sachs Primoris downgraded to Sell from Neutral at Goldman Sachs PRIM Primoris $22.52 / +0.095 (+0.42%) 05/09/22 Primoris raises FY22 adjusted EPS view to $2.49-$2.69 from $2.39-$2.59 05/09/22 Primoris reports Q1 adjusted EPS 1c, consensus 9c 02/28/22 Primoris sees FY22 EPS $2.39-$2.59, consensus $2.50 02/28/22 Primoris reports Q4 EPS 63c, consensus 56c 08/09/22 Primoris - PRIM
Syndicate	Merchants Bancorp files $500M mixed securities shelf 17:27 08/08/22 08/08 17:27 08/08/22 17:27 MBIN Merchants Bancorp $27.72 / +0.445 (+1.63%) ShowHide Related Items >><< Company News Earnings MBIN Merchants Bancorp $27.72 / +0.445 (+1.63%) 02/17/22 Merchants Bancorp raises quarterly dividend 17% to 7c from 6c per share MBIN Merchants Bancorp $27.72 / +0.445 (+1.63%) 04/28/22 Merchants Bancorp reports Q1 EPS $1.02, consensus $1.00
Earnings	Freshpet backs FY22 revenue view of at least $575M, consensus $582.72M » 17:27 08/08/22 08/08 17:27 08/08/22 17:27 FRPT Freshpet $56.39 / +1.895 (+3.48%) Sees FY22 adjusted EBITDA… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events FRPT Freshpet $56.39 / +1.895 (+3.48%) 06/22/22 Freshpet recalls select product due to potential Salmonella contamination FRPT Freshpet $56.39 / +1.895 (+3.48%) 05/20/22 Atlantic Equities Atlantic Equities sees more volatility for Freshpet, downgrades shares 05/20/22 Atlantic Equities Freshpet downgraded to Neutral from Overweight at Atlantic Equities 05/03/22 Cowen Freshpet price target lowered to $163 from $181 at Cowen 05/03/22 Oppenheimer Freshpet price target lowered to $110 from $120 at Oppenheimer FRPT Freshpet $56.39 / +1.895 (+3.48%) 17:25 Today Freshpet reports Q2 EPS (45c), consensus (14c) 05/02/22 Freshpet backs FY22 revenue view at least $575M, consensus $576.99M 05/02/22 Freshpet reports Q1 EPS (40c), consensus (39c) 02/28/22 Freshpet sees FY22 revenue $575M, consensus $562.4M 04 May FRPT Freshpet $56.39 / +1.895 (+3.48%) 05/20/22 Proven algorithm says sell these stocks now 05/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/13/22 Short Report: Upstart shorts take profits as stock craters on guidance cut 05/13/22 Proven algorithm says sell these stocks now 16:30 Today Freshpet - FRPT 08/11/22 Freshpet
Syndicate	Rallybio files $300M mixed securities shelf 17:25 08/08/22 08/08 17:25 08/08/22 17:25 RLYB Rallybio $10.61 / -0.54 (-4.84%) ShowHide Related Items >><< Company News Street Research Earnings RLYB Rallybio $10.61 / -0.54 (-4.84%) 06/02/22 Rallybio announces Jeffrey Fryer to retire from CFO position 05/25/22 Rallybio director sold $1.3M in common stock 05/10/22 Rallybio announces in-licensing of Sanofi's KY1066 RLYB Rallybio $10.61 / -0.54 (-4.84%) 02/22/22 JMP Securities Rallybio initiated with an Outperform at JMP Securities 08/23/21 Evercore ISI Rallybio initiated with an Outperform at Evercore ISI 08/23/21 Cowen Rallybio initiated with an Outperform at Cowen 08/23/21 Jefferies Rallybio initiated with a Buy at Jefferies RLYB Rallybio $10.61 / -0.54 (-4.84%) 05/10/22 Rallybio reports Q1 EPS (48c), consensus (45c) 03/15/22 Rallybio reports Q4 EPS (42c), consensus (39c)
Earnings	Freshpet reports Q2 EPS (45c), consensus (14c) » 17:25 08/08/22 08/08 17:25 08/08/22 17:25 FRPT Freshpet $56.39 / +1.895 (+3.48%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events FRPT Freshpet $56.39 / +1.895 (+3.48%) 06/22/22 Freshpet recalls select product due to potential Salmonella contamination FRPT Freshpet $56.39 / +1.895 (+3.48%) 05/20/22 Atlantic Equities Atlantic Equities sees more volatility for Freshpet, downgrades shares 05/20/22 Atlantic Equities Freshpet downgraded to Neutral from Overweight at Atlantic Equities 05/03/22 Cowen Freshpet price target lowered to $163 from $181 at Cowen 05/03/22 Oppenheimer Freshpet price target lowered to $110 from $120 at Oppenheimer FRPT Freshpet $56.39 / +1.895 (+3.48%) 05/02/22 Freshpet backs FY22 revenue view at least $575M, consensus $576.99M 05/02/22 Freshpet reports Q1 EPS (40c), consensus (39c) 02/28/22 Freshpet sees FY22 revenue $575M, consensus $562.4M 02/28/22 Freshpet reports Q4 EPS (21c), consensus (16c) 04 May FRPT Freshpet $56.39 / +1.895 (+3.48%) 05/20/22 Proven algorithm says sell these stocks now 05/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/13/22 Short Report: Upstart shorts take profits as stock craters on guidance cut 05/13/22 Proven algorithm says sell these stocks now 16:30 Today Freshpet - FRPT 08/11/22 Freshpet
Conference/Events	CTI BioPharma management to meet virtually with BTIG » 17:25 08/08/22 08/08 17:25 08/08/22 17:25 CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) In conjunction with the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) 06/10/22 CTI BioPharma presents data from pacritinib program at EHA 05/26/22 CTI BioPharma to present pivotal data on pacritinib program 04/14/22 CTI BioPharma's Vonjo included in NCCN Myeloproliferative Neoplasm guidelines 02/28/22 CTI BioPharma announces FDA accelerated approval of VONJO CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) 11:28 Today Stifel Global Blood Therapeutics downgraded to Hold from Buy at Stifel 07/07/22 Cowen Cowen starts CTI BioPharma at Outperform on 'high growth opportunity' 07/07/22 Cowen CTI BioPharma initiated with an Outperform at Cowen 04/14/22 Stifel Stifel reiterates Buy on CTI BioPharma following new treatment guidelines CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) 16:30 Today CTI BioPharma reports Q2 EPS (21c), consensus (20c) 05/12/22 CTI BioPharma reports Q1 EPS (23c), consensus (41c) 03/31/22 CTI BioPharma reports Q4 EPS (38c), consensus (28c) CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) 06/27/22 Fly Insider: American Woodmark, Coursera among week's notable insider trades 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 04/01/22 What You Missed On Wall Street On Friday 00:00 Today Biotechnology Conference 08/15/22 2022 Biotech Summer Summit 08/09/22 CTI BioPharma - CTIC CTIC CTI BioPharma $7.04 / -0.38 (-5.12%) 05/12/22 CTI BioPharma options imply 10.5% move in share price post-earnings 04/18/22 Unusually active option classes on open April 18th 03/31/22 CTI BioPharma options imply 5.3% move in share price post-earnings 03/24/22 CTI BioPharma options imply 7.9% move in share price post-earnings
Conference/Events	Legend Biotech management to meet with BTIG » 17:25 08/08/22 08/08 17:25 08/08/22 17:25 LEGN Legend Biotech $49.50 / -0.385 (-0.77%) BTIG Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events LEGN Legend Biotech $49.50 / -0.385 (-0.77%) 06/05/22 Legend Biotech presents results from CARTITUDE clinical development program 06/03/22 Legend Biotech announces FDA clearance of LB1908 IND application 05/26/22 Legend Biotech granted conditional marketing authorization for Carvykti by EC 05/09/22 Legend Biotech names Lori Macomber as CFO, effective immediately LEGN Legend Biotech $49.50 / -0.385 (-0.77%) 07/20/22 Canaccord Canaccord starts Arcellx at Buy, sees 'best-in-class' potential 06/16/22 BMO Capital Legend Biotech initiated with an Outperform at BMO Capital 05/31/22 Morgan Stanley Legend Biotech named Catalyst Driven Idea by Morgan Stanley 03/15/22 Barclays Legend Biotech initiated with an Overweight at Barclays LEGN Legend Biotech $49.50 / -0.385 (-0.77%) 06/01/22 Legend Biotech reports Q1 EPS (13c), consensus (46c) 03/18/22 Legend Biotech reports Q4 EPS (30c), consensus (41c) 27 Jul 16 Dec LEGN Legend Biotech $49.50 / -0.385 (-0.77%) 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports LEGN Legend Biotech $49.50 / -0.385 (-0.77%) 07/25/22 Fly Intel: After-Hours Movers 07/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/17/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 18:30 Today Legend Biotech

Conference/Events	Liquidia Technologies management to meet with BTIG » 17:25 08/08/22 08/08 17:25 08/08/22 17:25 LQDA Liquidia Technologies $5.35 / -0.01 (-0.19%) In conjunction with the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events LQDA Liquidia Technologies $5.35 / -0.01 (-0.19%) 08/01/22 Liquidia announces publication of long-term clinical data from INSPIRE study 07/25/22 Liquidia reports inducement grant under Nasdaq listing rule 07/19/22 Liquidia Technologies receives favorable ruling in IPR against UTC patent 07/19/22 USPTO says Liquidia established United Therapeutics' '793 patent 'unpatentable' LQDA Liquidia Technologies $5.35 / -0.01 (-0.19%) 07/22/22 Ladenburg Ladenburg starts Liquidia Technologies at Buy with $15 price target 07/22/22 Ladenburg Liquidia Technologies initiated with a Buy at Ladenburg 07/20/22 BTIG Liquidia Technologies price target raised to $17 from $14 at BTIG 05/31/22 BTIG Liquidia Technologies initiated with a Buy at BTIG LQDA Liquidia Technologies $5.35 / -0.01 (-0.19%) 05/12/22 Liquidia Technologies reports Q1 EPS (30c) vs. (21c) last year 15 Apr LQDA Liquidia Technologies $5.35 / -0.01 (-0.19%) 07/22/22 What You Missed On Wall Street On Friday 07/22/22 What You Missed On Wall Street This Morning 07/22/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/13/22 What You Missed On Wall Street On Wednesday 08/11/22 Liquidia Technologies - LQDA 18:00 Today Liquidia Technologies
Conference/Events	Andersons management to meet with Stephens » 17:25 08/08/22 08/08 17:25 08/08/22 17:25 ANDE Andersons $37.90 / -0.05 (-0.13%) Stephens holds a group… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ANDE Andersons $37.90 / -0.05 (-0.13%) 05/03/22 Andersons signs agreement to sell its railcar repair business ANDE Andersons $37.90 / -0.05 (-0.13%) 05/05/22 BMO Capital Andersons price target lowered to $45 from $50 at BMO Capital 03/25/22 Lake Street Andersons price target raised to $60 from $50 at Lake Street 02/17/22 Lake Street Andersons price target raised to $50 from $45 at Lake Street 11/29/21 Lake Street Andersons price target raised to $45 from $42 at Lake Street ANDE Andersons $37.90 / -0.05 (-0.13%) 08/02/22 Andersons reports Q2 adjusted EPS $2.39, consensus 98c 05/03/22 Andersons reports Q1 adjusted EPS 18c vs. 35c a year ago 02/15/22 Andersons reports Q4 adjusted EPS $1.14, consensus 66c 09/14/22 6th Annual Best Ideas Growth Conference: Big 6 18:00 Today Andersons
Syndicate	Cybin announces at-the-market equity program for up to $35M » 17:23 08/08/22 08/08 17:23 08/08/22 17:23 CYBN Cybin / + Cybin "announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events CYBN Cybin / + 07/12/22 Cybin begins trial enrollment for CYB003 study for MDD treatment 06/27/22 Cybin announces additional Adelia milestone achievement 06/27/22 Cybin receives FDA IND clearance for Phase 1/2a trial evaluating CYB003 06/09/22 Cybin gets IRB approval for Phase 1/2a clinical trial of CYB003 in MDD CYBN Cybin / + 06/23/22 Canaccord Cybin undervalued relative to market size opportunity, says Canaccord 06/10/22 Canaccord Cybin shares remain significantly undervalued, says Canaccord 04/13/22 H.C. Wainwright H.C. Wainwright says Cybin preclinical data show continued innovation leadership 11/23/21 Stifel Cybin price target lowered to C$8.25 from C$10 at Stifel CYBN Cybin / + 17:10 Today Cybin reports Q1 cash, cash equivalents C$42.5M 00:00 Today 42nd Annual Global I Growth Conference
Hot Stocks	Mersana to get $100M upfront fee from GSK for co-commercialization of XMT-2056 » 17:22 08/08/22 08/08 17:22 08/08/22 17:22 MRSN Mersana Therapeutics $5.24 / +0.215 (+4.28%) , GSK GSK plc $40.31 / -0.27 (-0.67%) Mersana Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MRSN GSK MRSN Mersana Therapeutics $5.24 / +0.215 (+4.28%) 16:35 Today Mersana Therapeutics trading resumes 16:00 Today Mersana Therapeutics trading halted, news pending 05/23/22 Mersana Therapeutics director Hack buys 216K shares of stock 05/19/22 Mersana announces FDA grant of orphan drug designation to XMT-2056 GSK GSK plc $40.31 / -0.27 (-0.67%) 10:43 Today GSK, IQVIA launch Vaccine Track platform 07/29/22 ViiV Healthcare presents five-year data at AIDS 2022 on fostemsavir 07/28/22 ViiV Healthcare announces data from unblinded phase of HPTN 084 study 07/28/22 GSK plc signs framework contract with EC for supply of Adjupanrix flu vaccine MRSN GSK MRSN Mersana Therapeutics $5.24 / +0.215 (+4.28%) 05/10/22 Baird Mersana Therapeutics price target lowered to $18 from $23 at Baird 05/09/22 H.C. Wainwright Mersana price target lowered to $19 from $24 at H.C. Wainwright 11/10/21 Baird Mersana Therapeutics price target lowered to $23 from $30 at Baird 10/14/21 BTIG Mersana Therapeutics assumed with a Buy at BTIG GSK GSK plc $40.31 / -0.27 (-0.67%) 14:58 Today UBS GSK plc price target lowered to 1,820 GBp from 1,860 GBp at UBS 08/05/22 Morgan Stanley GSK plc resumed with an Equal Weight at Morgan Stanley 07/21/22 Citi GSK plc resumed with a Neutral at Citi 07/20/22 UBS GSK plc price target lowered to 1,850 GBp from 1,876 GBp at UBS MRSN GSK MRSN Mersana Therapeutics $5.24 / +0.215 (+4.28%) 16:24 Today Mersana Therapeutics reports Q2 EPS (55c), consensus (52c) 05/09/22 Mersana Therapeutics reports Q1 EPS (59c), consensus (32c) 02/28/22 Mersana Therapeutics reports Q4 EPS (68c), consensus (67c) GSK GSK plc $40.31 / -0.27 (-0.67%) 07/27/22 GSK plc reports Q2 adjusted EPS 34.7p vs. 28.2p last year 04/27/22 GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER 04/27/22 GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year 04/13/22 GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B GSK GSK GSK plc $40.31 / -0.27 (-0.67%) 07/18/22 GSK CEO says split will help deal with 'perennial underperformance,' FT reports 06/27/22 GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says 06/27/22 GSK's Haleon chooses Citi, UBS as spinoff brokers, Bloomberg says 06/06/22 GSK rectal cancer trial yields remission in all 18 patients, NY Times reports MRSN GSK MRSN Mersana Therapeutics $5.24 / +0.215 (+4.28%) 04/14/22 What You Missed On Wall Street This Morning 02/09/22 Wall Street in Fives - Must Read Lists for Wednesday 02/09/22 Wall Street in Fives - Must Read Lists at Midday GSK GSK plc $40.31 / -0.27 (-0.67%) 08/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/18/22 What You Missed On Wall Street This Morning 07/18/22 Fly Intel: Pre-market Movers 06/24/22 What You Missed On Wall Street On Friday 06/08/22 Global Healthcare Conference 08/09/22 Wedbush PacGrow Healthcare Virtual Conference 09/10/22 ESMO Congress 2022 16:30 Today Mersana Therapeutics - MRSN GSK GSK GSK plc $40.31 / -0.27 (-0.67%) 07/29/22 GSK plc (ADR) call volume above normal and directionally bullish 07/22/22 Two new option listings and one option delisting on July 22nd 07/20/22 One new option listing and two option delistings on July 20th 07/08/22 GlaxoSmithKline call volume above normal and directionally bullish
Syndicate	Canoo files automatic mixed securities shelf 17:22 08/08/22 08/08 17:22 08/08/22 17:22 GOEV Canoo $3.95 / +0.26 (+7.05%) ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GOEV Canoo $3.95 / +0.26 (+7.05%) 16:52 Today Canoo sees second half of FY22 operating expenses $200M-$245M 07/14/22 Canoo's multi-purpose platform selected by Army for analysis & demostration 07/13/22 Canoo drops 5% after disclosing Walmart pact prevents sales to Amazon 07/13/22 Canoo says Walmart agreement prevents sales to Amazon GOEV Canoo $3.95 / +0.26 (+7.05%) 07/14/22 R.F. Lafferty Canoo price target lowered to $17 from $20 at R.F. Lafferty 07/13/22 H.C. Wainwright Canoo price target lowered to $10 from $15 at H.C. Wainwright 12/16/21 R.F. Lafferty Canoo price target raised to $21 from $19 at R.F. Lafferty 12/16/21 Roth Capital Roth Capital upgrades Canoo to Buy, raises price target to $14 GOEV Canoo $3.95 / +0.26 (+7.05%) 16:51 Today Canoo reports Q2 EPS (68c), consensus (53c) 05/10/22 Canoo reports Q1 EPS (54c), consensus (50c) 02/28/22 Canoo reports Q4 EPS (60c), consensus (51c) GOEV Canoo $3.95 / +0.26 (+7.05%) 02/11/22 Canoo has lost founders, key engineers post-SPAC, Business Insider reports GOEV Canoo $3.95 / +0.26 (+7.05%) 07/25/22 Fly Insider: CrossFirst Bankshares, Canoo among week's notable insider trades 07/23/22 Short Report: Revlon shorts recede, stock retreats as buyout news fades 07/18/22 What You Missed This Week in EVs and Clean Energy 07/16/22 Short Report: Canoo shorts going along for the ride 17:00 Today Canoo - GOEV GOEV Canoo $3.95 / +0.26 (+7.05%) 13:19 Today Canoo options imply 15.3% move in share price post-earnings 07/27/22 Largest borrow rate increases among liquid names 07/20/22 Largest borrow rate increases among liquid names 07/14/22 Unusually active option classes on open July 14th

Events

Earnings calls, analyst events, roadshows and more

LQDA
Today at 18:00

Liquidia Technologies Firm Sponsored Meetings

New York, NY
ANDE
Today at 18:00

Andersons Firm Sponsored Meetings

New York, NY
LEGN
Today at 18:30

Legend Biotech Firm Sponsored Meetings

New York, NY
BBIO
Today at 18:30

BridgeBio Firm Sponsored Meetings

New York, NY
YALA
Today at 20:00

Yalla - YALA Conference Calls
AVID ...
Tomorrow at 00:00

25th Annual Technology, Internet & Communications Virtual Conference Conferences

Virtual Conference
SYNA ...
Tomorrow at 00:00

23rd Annual Technology Leadership Forum Conferences

Vail, CO
Tomorrow at 00:00

Hot Wheels Bus Tour Conferences

New York/New Jersey
MTZ ...
Tomorrow at 00:00

8th Annual Communications Infrastructure Summit Conferences

Boulder, CO
Tomorrow at 00:00

7th Annual Wells Fargo FinTech & Technology Services Forum Conferences

Gurney's Newport Beach, Newport, RI

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord $0.59 MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities $1.78 PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist $12.40-12.70
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies $241.19 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity $5.00 3M Shares PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler $28.44 8M Shares SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital $16.01 8.5M Shares
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Five new option listings and one option delisting on April 20th

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access